logo

Paul Sondel, MD

Paul Sondel, MD

Pediatric Hematology & Oncology Madison, WI

Professor of Pediatrics, University Wisc

Office Address

Office Map
  • 600 Highland Ave
    1111 Highland Ave
    Madison, WI 53792
    Phone: (608) 263-6420
    Fax: (608) 263-0440

Dr. Sondel's Clinical Specialties & Interests

  • Pediatric Hematology & Oncology: General Pediatric Hematology & Oncology

Dr. Sondel's Education & Medical Training

  • University of WisconsinUniversity of WisconsinResidency, Pediatrics
  • University of Minnesota at FairviewUniversity of Minnesota at FairviewResidency, Pediatrics
  • Harvard Med SchHarvard Medical SchoolMedical School

Dr. Sondel's Certifications & Licensure

  • WI State Medical LicenseWI State Medical License1978 - 2015
  • American Board of PediatricsAmerican Board of PediatricsPediatrics

Dr. Sondel's Awards, Honors, & Recognition

  • The American Society for Clinical InvestigationElected MemberThe American Society for Clinical Investigation, 1988
  • Marquis Whos WhoWhos Who in Medicine and HealthcareMarquis Whos Who

Dr. Sondel's Clinical Trials

Dr. Sondel's Publications & Presentations

PubMed | Citations by Web of Science®

Grant Support

  • The Role Of KIR And Fcr Genotype In The Efficacy Of MAB And IL2 Immunotherapy
    The Role Of KIR And Fcr Genotype In The Efficacy Of MAB And IL2 ImmunotherapyNational Cancer Institute
    2012 - 2012
  • Antitumor Mechanisms Of Anti-Cd40/Cpg-Activated Macrophages
    Antitumor Mechanisms Of Anti-Cd40/Cpg-Activated MacrophagesNational Cancer Institute
    2008 - 2011
  • Phase I Study Of Fenretinide LXS Oral Powder In Patients With Neuroblastoma
    Phase I Study Of Fenretinide LXS Oral Powder In Patients With NeuroblastomaNational Center For Research Resources
    2007 - 2007
  • 131I-MIBG With Intensive Chemotherapy And Autologous Stem Cell Rescue
    131I-MIBG With Intensive Chemotherapy And Autologous Stem Cell RescueNational Center For Research Resources
    2006 - 2007
  • Clinical Development Of Hu14.18-Il2 Targeted Therapy
    Clinical Development Of Hu14.18-Il2 Targeted TherapyNational Cancer Institute
    2006 - 2011
  • Phase II Trial Of Hu1418-Il2 (Emd 273063) In Subjects With Advanced Melanoma
    Phase II Trial Of Hu1418-Il2 (Emd 273063) In Subjects With Advanced MelanomaNational Center For Research Resources
    2006 - 2007
  • Phase I Trial Of Hu14.18-Il-2 In Neuroblastoma And Other Gd2+ Tumors
    Phase I Trial Of Hu14.18-Il-2 In Neuroblastoma And Other Gd2+ TumorsNational Center For Research Resources
    2004 - 2004
  • T-Cell Independent Antitumor Mechanisms Of CD40 Ligation
    T-Cell Independent Antitumor Mechanisms Of CD40 LigationNational Cancer Institute
    2002 - 2005
  • Clinical Development Of Hu14.18 IL2 Targeted Therapy
    Clinical Development Of Hu14.18 IL2 Targeted TherapyNational Cancer Institute
    2000 - 2004
  • Phase I Study Of Taxol In Refractory Leukemia In Children
    Phase I Study Of Taxol In Refractory Leukemia In ChildrenNational Center For Research Resources
    1999 - 2002
  • Maintenance Treatment Of Therapy Refractory All W/ B43 PAP Immunotoxi
    Maintenance Treatment Of Therapy Refractory All W/ B43 PAP ImmunotoxiNational Center For Research Resources
    1999 - 2002
  • Antibody IL-2 Fusion Protein Delivery By Gene Transfer
    Antibody IL-2 Fusion Protein Delivery By Gene TransferNational Cancer Institute
    1996 - 1998
  • Clinical Testing Of Ch1418-Il2 For Gd2+ Tumors
    Clinical Testing Of Ch1418-Il2 For Gd2+ TumorsNational Cancer Institute
    1996 - 1998
  • Systemic Immunity By Particle Mediated BRM Gene Transfer
    Systemic Immunity By Particle Mediated BRM Gene TransferNational Cancer Institute
    1996 - 1999
  • Phase I Trial Of Melanoma Reactive Ch.14.18 PLUS IL2 In Adults With Melanoma
    Phase I Trial Of Melanoma Reactive Ch.14.18 PLUS IL2 In Adults With MelanomaNational Center For Research Resources
    1995 - 1996
  • In Vitro Reactivity And Regulation Of Lymphocyte Response In Lymphocytes
    In Vitro Reactivity And Regulation Of Lymphocyte Response In LymphocytesNational Center For Research Resources
    1995 - 1995
  • Combined Modality Antibody Directed Cell Cytotoxicity
    Combined Modality Antibody Directed Cell CytotoxicityNational Cancer Institute
    1995 - 1995
  • Immunobiology Of Antileukemic Lymphocytes
    Immunobiology Of Antileukemic LymphocytesNational Cancer Institute
    1994 - 1994
  • Combined Modality Antibody-Directed Cell Cytotoxicity
    Combined Modality Antibody-Directed Cell CytotoxicityNational Cancer Institute
    1993 - 1995
  • Antitumor Artificial Receptors As Cancer Vaccines
    Antitumor Artificial Receptors As Cancer VaccinesNational Cancer Institute
    1992 - 1995
  • BRM Monitoring Of Pediatric Neuroblastoma/Osteosarcoma
    BRM Monitoring Of Pediatric Neuroblastoma/OsteosarcomaNational Cancer Institute
    1990 - 1991
  • Immunobiology Of Human Antileukemic Lymphocytes
    Immunobiology Of Human Antileukemic LymphocytesNational Cancer Institute
    1990 - 1993
  • Clinical Studies Of Biological Response Modifiers
    Clinical Studies Of Biological Response ModifiersDivision Of Cancer Treatment
    1990 - 1994
  • Autologous LAK Cells &Il-2 In Cancer Patients
    Autologous LAK Cells &Il-2 In Cancer PatientsDivision Of Cancer Treatment
    1987 - 1990
  • Clinical Trial Of Natural And Recombinent Interleukin-2
    Clinical Trial Of Natural And Recombinent Interleukin-2Division Of Cancer Treatment
    1986 - 1986
  • The Immunobiology Of Human Antileukemic Lymphocytes
    The Immunobiology Of Human Antileukemic LymphocytesNational Cancer Institute
    1985 - 1989
  • Core--Scintillation Counting Services
    Core--Scintillation Counting ServicesNational Cancer Institute
    1985 - 1985

Dr. Sondel's Professional Memberships

Hospital Affiliations

Alternate Names

  • Dr. Paul Sondel, Dr. Paul Sondel, MD, Dr. P Sondel, Dr. Paul M Sondel

28 Colleague Invites!
Is this you? If so, register to see 28 messages.

Physicians, view Dr. Sondel's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV